A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
Running, not enrolling · Phase 1
Conditions studied: Alopecia Areata, Vitiligo
In brief
This is a multi-center, parallel-group, open-label, randomized, Phase 1b study to explore the safety, clinical activity, pharmacokinetics and pharmacodynamics of DR-01 in adults with Alopecia Areata or Vitiligo.
Key facts
- Study ID
- NCT06602232
- Run by
- Dren Bio
- People needed
- 81
- Starts
- 2024-10-30
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2026-07-08
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Dren Investigational Site — Northridge, California, United States
- Dren Investigational Site — Miami, Florida, United States
- Dren Investigational Site — Evans, Georgia, United States
- Dren Investigational Site — Meridian, Idaho, United States
- Dren Investigational Site — Indianapolis, Indiana, United States
- Dren Investigational Site — West Lafayette, Indiana, United States
- Dren Investigational Site — Worcester, Massachusetts, United States
- Dren Investigational Site — Troy, Michigan, United States
- Dren Investigational Site — Philadelphia, Pennsylvania, United States
- Dren Investigational Site — Pittsburgh, Pennsylvania, United States
- Dren Investigational Site — Chattanooga, Tennessee, United States
- Dren Investigational Site — San Antonio, Texas, United States
- Dren Investigational Site — Charlestown, New South Wales, Australia
- Dren Investigational Site — Darlinghurst, New South Wales, Australia
- Dren Investigational Site — Coorparoo, Queensland, Australia
- Dren Investigational Site — South Yarra, Victoria, Australia
- Dren Investigational Site — Fremantle, Washington, Australia
- Dren Investigational Site — Auckland, New Zealand
- Dren Investigational Site — Christchurch, New Zealand
- Dren Investigational Site — Grafton, New Zealand
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.